Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards.

NCT00730847 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00730847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00730847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards.
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Terminated
Start date
September 17, 2008
Completion date
January 16, 2012
Enrollment
743 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection leading to cervical cancer